Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017

Acta Oncologica

Volumn 36, Issue SUPPL. 9, 1997, Pages 1-49

  Hristova, Lora ^a,b,c   Hakama, Matti ^a,b  

^a FINNISH CANCER REGISTRY   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c Bulgarian Cancer Registry ^*  (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BREAST TUMOR; COLORECTAL TUMOR; COST; ECONOMICS; FEMALE; HEALTH CARE COST; HUMAN; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; MORTALITY; NEOPLASM; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SCANDINAVIA; SURVIVAL RATE; UTERINE CERVIX TUMOR;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; COSTS AND COST ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASMS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SCANDINAVIA; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 0030626116     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (138)

1. Engeland A, Haldorsen T, Tretli S, et al. Prediction of cancer incidence in the Nordic countries up to the years 2000 and 2010. APMIS 1993: 101(Suppl. 38).
2. Engeland A, Haldorsen T, Tretli S, et al. Prediction of cancer mortality in the Nordic countries up to the years 2000 and 2010. APMIS 1995; 103(Suppl. 49).
3. Miller AB, Chamberlain J, Day NE, Hakama M, Prorok PC (eds). Cancer screening. UICC Project on Evaluation of Screening for Cancer. Cambridge: International Union Against Cancer, 1991.
4. Hristova L. Effect of screening for cancer on mortality, costs and quality of life in Finland. (Doctoral thesis). Tampere: Acta Universitatis Tamperensis, ser A vol. 456, 1995.
5. Tabar L, Fagerberg G, Gad A, et al. Reduction in mortality from breast cancer after mass screening with mammography. Lancet 1985; 1: 829-832.
6. Hakama M, Elovainio L, Kajantie R, Louhivuori K. Breast cancer screening as public health policy in Finland. Br J Cancer 1991; 64: 962-964.
7. Sigfusson BF. Bröstcancerscreening med mammografi på Island - Program och resultat från första ronden. Reykjavik: Mammografiavdelningen, Isländska Cancerföreningen, 1992.
8. Törnberg S, Carstensen J, Hakulinen T, Lenner P, Hatschek T, Lundgren B. Evaluation of the effect on breast cancer mortality of population based mammography screening programmes. J Med Screening 1994; 1: 184-187.
9. Kronborg O, Fenger C, Olsen J. Interim report on a randomized trial of screening for colorectal cancer with Hemoccult - II. In: Miller AB, et al., eds. Cancer screening. Cambridge: IUAC, Cambridge University Press, 1991: 126-130.
10. Mandel JS, Bond JH, Church T, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. New Engl J Med 1993; 328: 1365-1371.
11. Winawer SJ, Flehinger BJ, Schottenfeld D, Miller DG. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. JNCI 1993; 85: 1311-1318.
12. Tulinius H, Sigvaldason H. Trends in incidence of female breast cancer in the Nordic countries. In: Magnus K, ed. Trends in cancer incidence. New York: Hemisphere Publishing Corporation, 1982: 235-247.
13. Hakulinen T, Andersen A, Malker B, Pukkala E, Schou G, Tulinius H. Trends in cancer incidence in the Nordic countries. APMIS 1986; 94(Suppl. 288).
14. Hakama M. Screening. In: Holland WW, Detels R, Knox G, eds. Oxford textbook of public health, vol. 3. Oxford University Press, 1990: 91-106.
15. Chamberlain J. Planning of screening programmes for evaluation and non-randomized approaches to evaluation. In: Prorok PC, Miller AB, eds. Screening for Cancer. Geneva: UICC, 1984: 5-17.
16. Day NE, Walter SD, Collette B. Statistical models of disease natural history: Their use in the evaluation of screening programmes. In: Prorok PC, Miller AB, eds. Screening for cancer. Geneva: UICC, 1984: 55-70.
17. Chamberlain J, Coleman D, Ellman R, et al. Sensitivity and specificity of screening in the UK trial of early detection of breast cancer In: Miller AB, et al., eds. Cancer screening. Cambridge: IUAC, Cambridge University Press, 1991: 3-17.
18. Chamberlain J, Moss SM, Kirkpatrick AE, Michell M, Johns L. National Health Service breast screening programme results for 1991-2. Br Med J 1993; 307: 353-356.
19. de Koning HJ, Fracheboud J, Boer R, et al. Nation-wide breast cancer screening in The Netherlands: support for breast-cancer mortality reduction. Int J Cancer 1995; 60: 777-780.
20. Moss SM, Coleman DA, Ellman R, et al. Interval cancers and sensitivity in the screening centres of the UK trial of early detection of breast cancer. Eur J Cancer 1993; 29A: 255-258.
21. Peeters PHM, Verbeek ALM, Hendriks JHCL, Holland R, Mravunac M, Vooijs GP. The occurrence of interval cancers in the Nijmeden screening programme. Br J Cancer 1989; 59: 929-932.
22. Woodman CBJ, Threlfall AG, Boggis CRM, Prior P. Is the three year breast screening interval too long? Occurrence of interval cancers in NHS breast screening programme's north western region. Br Med J 1995; 319: 224-226.
23. Lynge E. Screening for cancer of the cervix uteri. World J Surg 1989; 13: 71-78.
24. Sigurdsson K. Quality assurance in cervical cancer screening: the Icelandic experience 1964-1993. Eur J Cancer 1995; 31A: 728-734.
25. Kewenter J, Bjork S, Haglind E, Smith L, Svanvik J, Ahren C. Screening and rescreening for colorectal cancer: A controlled trial of faecal occult blood testing in 27 700 subjects. Cancer 1988; 62: 645-651.
26. Winawer SJ, Schottenfeld D, Flehinger BJ. Colorectal cancer screening. JNCI 1991; 83: 243-253.
27. Hakama M, Stenman U-H, Knekt P, et al. Tumour markers and screening for gastrointestinal cancer: a follow up study in Finland. J Med Screening 1994; 1: 60-64.
28. Sidransky D, Tokino T, Hamilton SR, et al. Identification of ras oncogene mutations in the stools of patients with curable colorectal tumours. Science 1992; 256: 102-105.
29. Hakama M. Screening for breast cancer in Finland. In: Miller AB et al. (eds). Cancer screening. UICC Project on Evaluation of Screening for Cancer. Cambridge: International Union Against Cancer, 1991: 18-22.
30. Hakama M. Potential contribution of screening to cancer mortality reduction. Cancer Detection and Prevention 1993; 17: 513-520.
31. Törnberg S. Experiences from the planning of general mammography screening in Stockholm. Mimeographed, 1989.
32. Hakama M, Joutsenlahti U, Virtanen A, Räsänen-Virtanen U. Mass screening for cervical cancer in Finland 1963-71. Ann Clin Res 1975: 7: 101-111.
33. Läärä E, Day N, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1987; 1: 1247-1249.
34. Petterson F, Björkholm E, Näslund I. Evaluation of screening for cervical cancer in Sweden: Trends in incidence and mortality 1958-1980. Int J Epidemiol 1985; 14: 521-527.
35. Lynge E, Madsen M, Engholm G. Effect of organized screening on incidence and mortality of cervical cancer in Denmark. Cancer Res 1989; 49: 2157-2160.
36. Bjorge T, Thorsen S, Skare G. Incidence, survival and mortality in cervical cancer in Norway, 1956-1990. Eur J Cancer 1993; 29A: 2291-2297.
37. Miller AB. Screening for cancer: issues and future directions. J Chron Dis 1986; 39: 1067-1077.
38. Miller AB, Chamberlain J, Day NE, Hakama M, Prorok PC. Report on a workshop of the UICC project on evaluation of screening for cancer. Int J Cancer 1990; 46: 761-769.
39. Moss SM, Ellman R, Coleman D, Chamberlain J. Survival of patients with breast cancer diagnosed in the United Kingdom trial of early detection of breast cancer. J Med Screening 1994; 1: 193-198.
40. Hutchison GB, Shapiro S. Lead time gained by diagnostic screening for breast cancer. JNCI 1968; 41: 665.
41. Feinleib M, Zelen M. Some pitfalls in the evaluation of screening programs. Arch Environm Health 1969; 19: 412.
42. Prorok PC. Methodological issues in randomized controlled trials of screening In: Prorok PC, Miller AB, eds. Screening for cancer. Geneva: UICC, 1984: 18-28.
43. Fletcher SW, Black W, Harris R, Rimer BK, Shapiro S. Report of the International Workshop on screening for breast cancer. JNCI 1993; 85: 1644-1656.
44. Wald NJ, Chamberlain J, Hackshaw A. Report of the European Society for Mastology breast cancer screening evaluation committee 1993. The Breast 1993; 2: 209-216.
45. Shapiro S, Venet W, Strax P, Venet L. Current results of the breast cancer screening randomized trial: The Health Insurance Plan (HIP) of Greater New York Study. In: Day NE, Miller AB, eds. Screening for breast cancer. Hans Huber Publishers, 1988: 3-17.
46. Nyström L, Rutqvist LE, Wall S, et al. Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet 1993; 341: 973-978.
47. Miller AB, Baines CJ, To T, Wall C. The Canadian National Breast Screening Study. In: Miller AB, et al. (eds). Cancer screening. UICC Project on Evaluation of Screening for Cancer. Cambridge: International Union Against Cancer, 1991: 45-55.
48. Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years. Can Med Assoc J 1992; 147: 1459-1476.
49. Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years. Can Med Assoc J 1992; 147: 1477-1488.
50. Fidler HK, Boyes DA, Worth AJ. Cervical cancer detection in British Columbia. J Obstet Gynaecol Br Commonw 1968; 75: 392-404.
51. Miller AB. The Canadian experience of cervical cancer: incidence trends and a planned natural history investigation. In: Magnus K, ed. Trends in cancer incidence. New York: Hemisphere Publishing Corporation, 1982: 311-320.
52. Hakama M, Räsänen-Virtanen U. Effect of a mass screening program on the risk of cervical cancer. Am J Epidemiology 1976; 103: 512-517.
53. Gustafsson L, Adami HO. Cytological screening for cancer of the uterine cervix in Sweden evaluated by identification and simulation. Br J Cancer 1990; 61: 903-908.
54. Hakama M. Trends in the incidence of cervical cancer in the Nordic countries. In: Magnus K, ed. Trends in cancer incidence. New York: Hemisphere Publishing Corporation, 1982: 279-292.
55. Sigurdsson K, Adalsteinsson S, Tulinius H, Ragnarsson J. The value of screening as an approach to cervical cancer control in Iceland, 1964-1986. Int J Cancer 1989; 43: 1-5.
56. Sigurdsson K. Effect of organized screening on the risk of cervical cancer. Evaluation of screening activity in Iceland, 1964-1991. Int J Cancer 1993; 54: 563-570.
57. Palli D, Carli S, Cecchini S, Venturini A, Piazzesi G, Buiatti E. A centralised cytology screening programme for cervical cancer in Florence. J Epidemiol Community Health 1990; 44: 47-51.
58. Cuzick J. The organization of cervical screening in England and Wales. In: Miller AB, et al. (eds). Cancer screening. UICC Project on Evaluation of Screening for Cancer. Cambridge: International Union Against Cancer, 1991: 163-171.
59. Flehinger BJ, Herbert E, Winawer SJ, Miller DG. Screening for colorectal cancer with fecal occult blood test and sigmoidoscopy: Preliminary report of the colon project of Memorial Sloan-Kettering Cancer Centre and PMI-Strang Clinic. In: Chamberlain J, Miller AB, eds. Screening for gastrointestinal cancer. Toronto: Huber, 1988: 9-16.
60. Church TR, Mandel JS, Bond JH, et al. Colon cancer control study: Status and current issues. In: Miller AB, et al., eds. Cancer screening. Cambridge: IUAC, Cambridge University Press, 1991: 83-105.
61. Hardcastle JD, Farrands PA, Balfour TW, Chamberlain J, Amar SS, Sheldon MG. Controlled trial of faecal occult blood testing in the detection of colorectal cancer. Lancet 1983; 2: 1-4.
62. Hardcastle JD, Chamberlain J, Sheffield J, et al. Randomised, controlled trial of faecal occult blood screening for colorectal cancer. Lancet 1989; 1: 1160-1164.
63. Thomas WM, Hardcastle JD. An update on the Nottingham trial of faecal occult blood screening for colorectal carcinoma. In: Miller AB, et al., eds. Cancer screening. Cambridge: IUAC, Cambridge University Press, 1991: 106-115.
64. Kewenter J, Asztely M, Engaras B, Haglind E, Svanvik J, Ahren C. A randomised trial of faecal occult blood testing for early detection of colorectal cancer. Results of screening and rescreening of 51325 subjects. In: Miller AB, et al., eds. Cancer screening. UICC Project on Evaluation of Screening for Cancer. Cambridge: International Union Against Cancer, 1991: 116-125.
65. Kronborg O, Fenger C, Sondergaard O, Pedersen KM, Olsen J. Initial mass screening for colorectal cancer with faecal occult blood test. Scand J Gastroenterol 1987; 22: 677-686.
66. Dent OF, Bartrop R, Goulston KJ, Chapuis PH. Participation in faecal occult blood screening for colorectal cancer. Soc Sci Med 1983; 17: 17-23.
67. Fontana RS. Early detection of lung cancer: the Mayo lung project. In: Prorok PC, Miller AB, eds. Screening for cancer. I. General principles on evaluation of screening for cancer and screening for lung, bladder and oral cancer. Geneva: UICC Technical Report Series 78, 1984: 107-122.
68. Kubik A, Parkin M, Khlat M, Erban J, Polak J, Adamec M. Lack of benefit from semi-annual screening for cancer of the lung: Follow-up report of a randomized controlled trial on a population of high-risk males in Czechoslovakia. Int J Cancer 1990; 45: 26-33.
69. Pearson VAH. Screening for ovarian cancer: A review. Public Health 1994; 108: 367-382.
70. Hisamichi S, Fukao A, Sugawara N, et al. Evaluation of mass screening programme for stomach cancer in Japan. In: Miller AB, et al., eds. Cancer screening. UICC Project on Evaluation of Screening for Cancer. Cambridge: International Union Against Cancer, 1991: 357-370.
71. Miller AB. Issues in screening for prostate cancer. In: Miller AB, et al., eds. Cancer screening. UICC Project on Evaluation of Screening for Cancer. Cambridge: International Union Against Cancer, 1991: 289-293.
72. Fitzpatrick R, Fletcher A, Gore S, Jones D, Spiegelhalter D, Cox D. Quality of life measures in health care. I: Applications and issues in assessment. Br Med J 1992; 305: 1074-1077.
73. Schumacher M, Olschewski M, Schulgen G. Assessment of quality of life in clinical trials. Stat Med 1991; 10: 1915-1930.
74. Bliss JM, Selby PJ, Robertson B, Powles TJ. A method for assessing the quality of life of cancer patients: replication of the factor structure. Br J Cancer 1992; 65: 961-966.
75. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. JNCI 1993; 85: 365-376.
76. Fletcher A, Gore S, Jones D, Fitzpatrick R, Spiegelhalter D, Cox D. Quality of life measures in health care. II: Design, analysis, and interpretation. Br Med J 1992; 305: 1145-1148.
77. Cox DR, Fitzpatrick R, Fletcher AE, Gore SM, Spiegelhalter J, Jones DR. Quality of life assessment: can we keep it simple? J R Stat Soc 1992; 155: 353-393.
78. Aaronson NK, Bullinger M, Ahmedzai S. A modular approach to quality-of-life assessment in cancer clinical trials. Rec Res Cancer Res 1988; 111: 231-249.
79. Heyink J. Adding years to your life or adding life to your years. Int J Health Sciences 1990; 1: 45-49.
80. Nord E. Methods for quality adjustment of life years. Soc Sci Med 1992; 34: 559-569.
81. Dean C, Roberts MM, French K, Robinson S. Psychiatric morbidity after screening for breast cancer. J Epidemiol Community Health 1986; 40: 71-75.
82. Cockburn J, Staples M, Hurley SF, de Luise T. Psychological consequences of screening mammography. J Med Screening 1994; 7: 7-12.
83. de Haes JCJM, de Koning HJ, van Oortmarssen GJ, van Agt HME, de Bruyn AE, van der Mass PJ. The impact of breast cancer screening programme on quality-adjusted life-years. Int J Cancer 1991; 49: 538-544.
84. de Koning HJ, van Ineveld BM, van Oortmarssen GJ, et al. Breast cancer screening and cost effectiveness; policy alternatives, quality of life considerations and possible impact of uncertain factors. Int J Cancer 1991; 49: 531-537.
85. Katz S, Branch LG, Branson MH, Papsidero JA, Beck JC, Greer DS. Active life expectancy. N Engl J Med 1983; 309: 1218-1224.
86. Hofman A, Rocca WA, Brayne C, et al. The prevalence of dementia in Europe: A collaborative study of 1980-1990 findings. Int J Epidemiology 1991; 20: 736-748.
87. Skoog I, Nilsson L, Palmertz B, Andreasson LA, Svanborg A. A population-based study of dementia in 85-year-olds. N Engl J Med 1993; 328: 153-158.
88. Roelands M, van Oyen H, Baro F. Dementia-free life expectancy in Belgium. Eur J Public Health 1994; 4: 33-37.
89. Grimby A, Wiklund I. Health-related quality of life in old age. A study among 76-year-old Swedish urban citizens. Scand J Soc Med 1994; 1: 7-14.
90. Holmen K, Ericsson K, Winblad B. Loneliness and living conditions of the oldest old. Scand J Soc Med 1994; 1: 15-19.
91. Strauss MJ, Bleecker GC, Steinwald AB. Cost-effectiveness analysis in a changing health care environment: New issues and challenges. Eur J Cancer 1993; 76 29A: S3-S5.
92. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1987.
93. Holli K, Hakama M, Hakala T. Use of hospital services by breast cancer patients by stage of the disease: Implications on the costs of cancer control. Breast Cancer Res Treat 1996; 37: 237-241.
94. de Koning HJ, van Ineveld BM, de Haes JCJM, van Oortmarssen GJ, Klijn JGM, van der Mass PJ. Advanced breast cancer and its prevention by screening. Br J Cancer 1992; 65: 950-955.
95. Bonsel GJ, Rutten FFH, Groot CAU. Economic evaluation alongside cancer trials: methodological and practical aspects. Eur J Cancer 1993; 29A: S10-S14.
96. Working group chaired by Professor Sir Patrick Forrest. Breast cancer screening. London: Her Majesty's Stationery Office, 1987.
97. Alban A, Pedersen KM. The economics of screening. In: Hugod C, Fog J, eds. Screening: Why, when, and how? Copenhagen: N Olaf Moller, 1992: sivut?
98. Cairns JA, Shackley P. Assessing value for money in medical screening. J Med Screening 1994; 1: 30-44.
99. Greenwald P, Sondik E, eds. NCI Monographs. Cancer control objectives for the nation: 1985-2000. NIH Publication No. 86-2880, 1986.
100. Koopmanschap MA, Lube KTN, van Oortmarssen GJ, van Agt HMA, van Ballegooijen M, Habbema JDF. Economic aspects of cervical cancer screening. Soc Sci Med 1990; 30: 1081-1087.
101. Eddy DM. Common screening tests. Philadelphia: American College of Physicians, 1991.
102. Shimbo T, Glick H, Eisenberg JM. Cost-effectiveness analysis of strategies for colorectal cancer screening in Japan. Int J Technology Assessment in Health Care 1994; 10: 359-375.
103. White E, Urban N, Taylor V. Mammography utilization, public health impact, and cost-effectiveness in the United States. Ann Rev Publ Health 1993; 14: 605-633.
104. Pedersen KM. Economics of cancer screening: total costs and benefits in economic terms. Eur J Cancer 1994; 30A: 873-875.
105. Beemsterboer PMM, de Koning HJ, Warmerdam PG, et al. Prediction of the effects and costs of breast-cancer screening in Germany. Int J Cancer 1994; 58: 623-628.
106. van Ineveld BM, van Oortmarssen GJ, de Koning HJ, Boer R, van der Mass PJ. How cost-effective is breast cancer screening in different EC countries? Eur J Cancer 1993; 29A: 1663-1668.
107. Hakulinen T, Abeywickrama KH. A computer program package for relative survival analysis. Comp Progr Biomed 1985; 19: 197-207.
108. Hakama M, Hakulinen T. Estimating the expectation of life in cancer survival studies with incomplete follow-up information. J Chron Dis 1977; 30: 585-697.
109. Official Statistics of Finland. Life tables 1981-85. VI A:152. Helsinki: Central Statistical Office of Finland, 1987.
110. Breslow NE, Day NE. Statistical methods in cancer research. Vol II: The design and analysis of cohort studies. Lyon: IARC Scientific Publications No.82, 1987.
111. McCullach P, Neider JA. Generalized linear models. Cambridge: University Press, Cambridge, 1989.
112. Myers MH, Hankey BM, Steinhorn SC, Flannery J. Interrelationships of incidence, survival, and mortality and their effects on time trends. In: Magnus K, ed. Trends in cancer incidence. New York: Hemisphere Publishing Corporation, 1982: 79-87.
113. Muir CS. Time trends as indicators of etiology. In: Magnus K, ed. Trends in cancer incidence. New York: Hemisphere Publishing Corporation, 1982: 89-102.
114. Day N, Charnay B. Time trends, cohort effects, and ageing as influence on cancer incidence. In: Magnus K, ed. Trends in cancer incidence. New York: Hemisphere Publishing Corporation, 1982: 51-65.
115. Aitkin M, Anderson D, Francis B, Hinde J. Statistical Modeling in GLIM. Oxford: Clarendon Press, 1989.
116. Koopmanschap MA, van Roijen L, Bonneux L, Barendregt JJ. Current and future costs of cancer. Eur J Cancer 1994; 30A: 60-65.
117. Ciatto S, Rosselli del Turco M, Giorgi D, et al. Assessment of lesions detected at mammographic screening: performance at first or repeat screening in the Florence programme. J Med Screening 1994; 1: 188-192.
118. Janzon L, Andersson I. The Malmö mammographic screening trial. In: Miller AB, et al., eds. Cancer screening. UICC Project on Evaluation of Screening for Cancer. Cambridge: International Union Against Cancer, 1991: 37-44.
119. Finnish Cancer Registry. Cancer Incidence in Finland 1992. Helsinki: Cancer Society of Finland Publication No. 54, 1994.
120. Beral V, Hermon C, Muñoz N, Devesa SS. Cervical cancer. Trends in cancer incidence and mortality. Cancer Surveys 1994; 19/20: 265-285.
121. IARC Working group on evaluation of cervical cancer screening programmes. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. Br Med J 1986; 293: 659-664.
122. Walker A, Whynes DK, Chamberlain JO, Hardcastle JD. The cost of screening for colorectal cancer. J Epidemiol Community Health 1991; 45: 220-224.
123. Brown ML, Nayfield G, Shibley LM. Adjuvant therapy for stage III colon cancer: economics returns to research and cost-effectiveness of treatment. JNCI 1994; 86: 424-430.
124. Elixhauser A. Costs of breast cancer and the cost-effectiveness of breast cancer screening. Int J Technol Assessment in Health Care 1991; 7: 604-615.
125. Brown ML. Economic considerations in breast cancer screening of older women. J Geront 1992; 47: 51-58.
126. US Office of Technology Assessment. Breast cancer screening for medicare beneficiaries: effectiveness, costs of medicare and medical resources required. Washington, DC: US Congress Office of Technology Assessment and Health Progress, 1987.
127. Taplin SH, Barlow W, Urban N, et al. Stage, age, comorbidity, and direct cost of colon, prostate, and breast cancer care. JNCI 1995; 87: 417-426.
128. van Ballegooijen M, Boer R, van Oortmarssen GJ, Koopmanschap MA, Lubbe JTN, Habbema JDF. Bevolkingsonderzoek op baarmoederhalskanker: leeftijdsgrenzen en intervallen. Rotterdam: Instituut Maatschappelijke Gezondheidszorg, Erasmus Universiteit, 1993.
129. Habbema JDF, van Oortmarssen GJ. To screen or not to screen. How do we decide on which cancer screening activities to embark upon? Eur J Cancer 1994; 30A: 884-886.
130. Russel LB. Is prevention better than cure? Washington: The Brookings Institution, 1986.
131. van Ballegooijen M, Habbema JDF, van Oortmarssen GJ, Koopmanschap MA, Lubbe JTN, van Agt HME. Preventive PAP-smears: balancing costs, risks and benefits. Br J Cancer 1992; 65: 930-933.
132. van Ballegooijen M, Koopmanschap MA, Tjokrowardojo AJS, van Oortmarssen GJ. Care and costs for advanced cervical cancer. Eur J Cancer 1992: 28A: 1703-1708.
133. Koopmanschap MA, van Ineveld BM, Miltenburg TEM. Costs of home care for advanced breast and cervical cancer in relation to cost-effectiveness of screening. Soc Sci Med 1992; 35: 979-985.
134. Hall J, Gerard K, Salkeld G, Richardson J. A cost utility analysis of mammography screening in Australia. Soc Sci Med 1992; 34: 993-1004.
135. Kauppinen MA, Kauraniemi T, Koli T, Voipio N. Response to the written invitation in a gynecological mass screening by cytology arranged in Helsinki in 1966. Acta Obstet Gynecol Scand 1970; 49(Suppl. 7).
136. Fisher B, Redmond C, Poisson R, et al. Eight-year results in a randomized clinical trial comparing total mastectomy and lumpectomy with or without radiation in treatment of breast cancer. N Engl J Med 1989; 320: 822-828.
137. Noguchi M, Kitagawa H, Kinoshita K, et al. Psychologic and cosmetic self-assessments of breast-conserving therapy compared with mastectomy and immediate breast reconstruction. J Surg Oncol 1993; 54: 260-266.
138. Carlsson M, Hamrin E. Psychological and psychosocial aspects of breast cancer and breast cancer treatment. Cancer Nurs 1994; 17: 418-428.